Vifor Pharma Nordiska AB - a company with extensive experience.
Vifor Pharma Nordiska AB is the Nordic affiliate of Vifor Pharma Ltd.
Together with Vifor Pharma Ltd. we share more than 50 years of experience from the field of iron deficiency and iron deficiency anaemia treatment. Vifor Pharma Ltd. is a Swiss-based pharmaceutical company owned by Galenica Ltd. which is noted on the Swiss stock exchange.
Vifor Pharma Nordiska AB is a Nordic organization with presence in Sweden, Denmark, Norway and Finland. On Iceland we are represented by the Icelandic company Vistor. The Nordic affiliate is responsible for the marketing and sales of the intravenous iron products Venofer® and Ferinject®.
Vifor Pharma Nordiska manages the products Ferinject® and Venofer® in the Nordic countries.
Since year 2008 Vifor Pharma Nordiska AB (formerly Renapharma Vifor) has managed the sales of the intravenous iron business from its prior distributor Renapharma AB, thus creating its own independent sales, medical and marketing infrastructure, based in the Stockholm region covering all Nordic countries.
In October 2008 Vifor Pharma launches Ferinject® in the Nordic countries.
Vifor Pharma and Fresenius Medical Care, the world's largest provider of dialysis products and services, enter into an exclusive license agreement for Venofer® and Ferinject® to treat iron-deficiency anaemia experienced by dialysis patients.
The registration files for the new iron-based product Ferinject® were submitted in Switzerland and in 18 countries of the EU in 2006 and approved in 2007. In November 2007, it was successfully launched in Germany.
Vifor (International) Ltd. sign long-term co-operation agreements to market existing and future iron products on the US market. The FDA (US Food and Drug Administration) approves Venofer® for treating iron-based anaemia in pre-dialysis patients in the USA.
Torshamnsgatan 30 A
SE-164 40 Kista